By blocking the final pathway of platelet aggregation and inhibiting inflammatory reaction, glyco-protein Ⅱb/Ⅲa receptor antagonist (GPI) prevents the formation of thrombosis. Its anti-thrombus effect is obviously stronger than aspirin and clopidogrel, and it have been confirmed by some experiments to improve the prognosis of pa-tients with acute coronary syndrome (ACS). In particular, the occurrence of slow flow and no reflow after percutaneous coronary intervention (PCI) was reduced, and the major adverse car-diac event (MACE) was also reduced, with no in-crease in the risk of bleeding. The function of GPI on ACS is targeted and specific. This paper reviews the literature at home and abroad in recent years.%血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂(GPI)通过阻断血小板凝集的最后通路抑制炎性反应,防止血栓形成.其抗栓作用明显强于阿司匹林及氯吡格雷,已有实验证实其能够改善急性冠脉综合征(ACS)患者的预后,特别是减少了经皮冠状动脉介入治疗术(PCI术)后慢血流及无复流的发生,同时还降低了心血管事件(MACE)的发生,且不增加出血风险.由于GPI对于ACS的作用具有明显的针对性、特异性,为此,本文参考近年来国内外有关文献进行综述.
展开▼
